The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) has earned renewal of its National Cancer Institute (NCI) designation as a Comprehensive Cancer Center for another five years.
The distinction recognizes the cancer center’s scientific leadership and programs in basic, clinical and population science research, placing it in the top echelon of cancer centers nationwide.
The cancer center, a joint entity of the University of Maryland Medical Center (UMMC) and the University of Maryland School of Medicine (UMSOM), has been approved to receive a support grant of nearly $13 million from the NCI over the next five years, a 14% increase over the previous five-year grant award.
UMGCCC was named an NCI-designated cancer center in 2008 and was elevated to the NCI’s highest designation of Comprehensive Cancer Center status in 2016.
As of December 2020, UMGCCC’s total cancer research funding was $100.9 million ($78.9 million in direct funding), up from $56.7 million ($46.6 million in direct funding) when the cancer center first applied for Comprehensive Cancer Center status in 2016. With an NCI designation, cancer centers are better able to leverage additional resources for cancer research, education and care.
There are about 1,500 cancer centers in the United States, and UMGCCC is one of only 51 NCI-designated Comprehensive Cancer Centers.